Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNF-blocking agents

Show full item record



Permalink

http://hdl.handle.net/10138/311875

Citation

Molander , P , Farkkila , M , Kemppainen , H , Blomster , T , Jussila , A , Mustonen , H & Sipponen , T 2017 , ' Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNF-blocking agents ' , Scandinavian Journal of Gastroenterology , vol. 52 , no. 3 , pp. 284-290 . https://doi.org/10.1080/00365521.2016.1250942

Title: Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNF-blocking agents
Author: Molander, Pauliina; Farkkila, Martti; Kemppainen, Helena; Blomster, Timo; Jussila, Airi; Mustonen, Harri; Sipponen, Taina
Contributor: University of Helsinki, Department of Medicine
University of Helsinki, Clinicum
University of Helsinki, Clinicum
University of Helsinki, Gastroenterologian yksikkö
Date: 2017
Language: eng
Number of pages: 7
Belongs to series: Scandinavian Journal of Gastroenterology
ISSN: 0036-5521
URI: http://hdl.handle.net/10138/311875
Abstract: Background: Little data exist on the long-term prognosis of patients with inflammatory bowel disease (IBD) after stopping TNF alpha-blocking therapy in deep remission. Existing data indicate that approximately 50% of patients on combination therapy who discontinued TNF alpha-blockers are still in remission 24 months later. The aims of this follow-up analysis were to evaluate the long-term remission rate after cessation of TNF alpha-blocking therapy, the predicting factors of a relapse and the response to restarting TNF alpha-blockers. Methods: The first follow-up data of 51 IBD patients (17 Crohn's disease [CD], 30 ulcerative colitis [UC] and four inflammatory bowel disease type unclassified [IBDU]) in deep remission at the time of cessation of TNF alpha-blocking therapy have been published earlier. The long-term data was collected retrospectively after the first follow-up year to evaluate the remission rate and risk factors for the relapse after a median of 36 months. Results: After the first relapse-free year, 14 out of the remaining 34 IBD patients relapsed (41%; 5/12 [42%] CD and 9/22 [41%] UC/IBDU). Univariate analysis indicated no associations with any predictive factors. Re-treatment was effective in 90% (26/29) of patients. Conclusion: Of IBD patients in deep remission at the time of cessation of TNF alpha-blocking therapy, up to 60% experience a clinical or endoscopic relapse after a median follow-up time of 36 months (95% CI 31-41 months). No individual risk factors predicting relapse could be identified. However, the initial response to a restart of TNF alpha-blockers seems to be effective and well tolerated.
Subject: Crohn's disease
ulcerative colitis
relapse
stopping
TNF alpha-antagonist
infliximab
adalimumab
CROHNS-DISEASE
INFLIXIMAB THERAPY
CLINICAL REMISSION
ULCERATIVE-COLITIS
BIOLOGICAL THERAPY
SINGLE-CENTER
FOLLOW-UP
MAINTENANCE
ANTIBODIES
RELAPSE
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
long_term_outcome.pdf 493.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record